key: cord-0975611-q452qs0j
authors: Saracco, Margherita; Romagnoli, Renato; Martini, Silvia
title: Solid non‐lung organs from COVID‐19 donors in seropositive or naive recipients: Where do we stand?
date: 2021-11-19
journal: Transpl Infect Dis
DOI: 10.1111/tid.13761
sha: 7f9dd0abb349f0048be047e35dab159b3665a46c
doc_id: 975611
cord_uid: q452qs0j

nan

We read with great interest the Eichenberger's editorial 1 and as suggested by the Authors, we would like to share the data from our Liver Transplant (LT) Center in Turin, Italy.

In our view, an accurate definition of coronavirus disease-19 (COVID-19) donor, as recently updated by Organ Procurement and Transplantation Network (OPTN) 2 is deemed to be crucial in order to standardize the worldwide experience and to balance the risk of SARS-CoV-2 donor transmission with the threat of dying from the underlying chronic disease.

According to the Literature, individuals who are convalescent from COVID-19 have a significantly lower risk of infection, because they are very likely to be protected by natural immunity. 3 Therefore, non-lung organs from COVID-19 donors can be transplanted into informed recipients with ongoing or resolved SARS-CoV-2 infection, 1,3 who might otherwise have limited opportunities for transplant due to disease acuity. drugs or monoclonal antibody and none of them developed COVID-19 after LT, as detailed in Table   1 .

In the same table, we reported the 45 published cases of transplants which were performed from 21 COVID-19 donors (classification according to OPTN: 2 mild, 7 resolved, 4 severe, 8 not classifiable) into 10 vaccinated recipients (8 kidneys and 2 livers) and 35 naive/asymptomatic recipients (19 kidneys, 7 hearts and 9 livers). None of these 45 subjects developed COVID-19 after transplant. One heart recipient 4 was preemptively treated with remdesivir (once in the preoperative period followed by two additional doses) plus Casirivimab-Imdevimab and 2 patients (1 naive heart recipient and 1 vaccinated liver recipient) 5 were treated with Casirivimab-Imdevimab on day 1 after transplant.

In conclusion, even though more solid data are needed, we agree with Eichenberger that the use of non-lung grafts from well-categorized COVID-19 donors might represent a precious source not only in previous symptomatic COVID-19, but also in patients with documented evidence of humoral immunity resulting either from asymptomatic infection, from vaccination or from long-acting monoclonal antibody infusion. 

The pandemic provides a pathway: What we know and what we need to know about using COVID positive donors

Summary of Current Evidence and Information-Donor SARS-CoV-2 Testing & Organ Recovery from Donors with a History of COVID-19. Version Release Date

Acknowledgements and Funding: the authors receive no financial support for whis work.Disclosures: the authors have nothing to disclose.